Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

This review discusses the range of cutaneous immune-related adverse events induced by immune checkpoint inhibitors and the proposed mechanisms underlying these skin reactions, but reports no new clinical results.

This review discusses the characteristics and treatment recommendations for skin-related adverse effects from immune checkpoint inhibitors in cancer treatment, and notes an observed association with favorable oncology outcomes that requires careful interpretation.

This review discusses the characteristics and management of cutaneous immune-related adverse events from immune checkpoint inhibitors and notes their potential association with a favorable cancer treatment response.

This study analyzed FAERS data to explore the risk and onset patterns of autoimmune skin diseases associated with immune checkpoint inhibitors, finding a strong association particularly with bullous pemphigoid and emphasizing the need for vigilant monitoring of these adverse effects.

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.

This study demonstrated that combining l-cystine and thiamin in a formulation may protect against UV-induced damage in growth-limited human epidermal keratinocytes in vitro.

This case report describes the first known occurrence of alopecia areata associated with cemiplimab, an anti-PD1 drug, in a patient with a positive cancer treatment response.

This article reviews the cutaneous side effects of immune checkpoint inhibitors and targeted therapies for skin cancers, noting that while generally mild, these effects can influence treatment decisions and quality of life, underscoring the need for physicians to be aware of these adverse reactions.

This study reviews the potential of rosemary extract for promoting hair growth and reducing hair fall, noting that its efficacy is comparable to minoxidil and that it is generally safe for topical use, though further clinical trials are needed to standardize formulations and dosages.

This study introduced a deep learning framework combining multiple convolutional neural networks to detect scalp and hair disorders and classify hair fall stages, reporting higher precision and robustness in detection and classification compared to individual CNN models.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

In this study, lung cancer patients undergoing treatment with immune checkpoint inhibitors and chemotherapy reported high incidence and severity of symptoms such as fatigue, drowsiness, and loss of appetite, which were most prominent and distressing throughout the treatment cycles.

This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

This study found that tumor immunotherapy, while effective against solid tumors, can disrupt the immune balance in hair follicles, causing follicular toxicity and alopecia, highlighting the need for targeted interventions to manage these adverse effects.

In this randomized study, patients with early favorable Hodgkin lymphoma showed similar complete remission and survival rates whether receiving 2 or 4 cycles of ABVD and 20 Gy or 30 Gy IFRT, though reduced toxicity was associated with fewer cycles and lower radiation doses.

This review discusses the increasing prevalence of erectile dysfunction in young men and emphasizes the importance of identifying specific causes for effective management, reporting no new clinical results.

This review explores the current understanding of genetic and hormonal influences on male androgenetic alopecia and female pattern hair loss, providing guidance for clinicians but reports no new results.

This review discusses botulinum toxin's experimental off-label uses in dermatology, highlighting promising results but emphasizing the need for more clinical trials to confirm efficacy and safety.

This report presents the second known case of erythema nodosum without typical associated conditions, which could be linked to mycoplasma infection, although no testing was conducted to confirm this in the patient.

Genetic research has advanced our understanding of skin diseases, but complex conditions require an integrative approach for deeper insight.

This article discusses the dynamics of the "mole gaze" and cybersexism on the Web, analyzing interactions through personal and theoretical lenses, and suggests the need for both structural and psychological change to counteract these issues.

This article overviews dermatologic findings in forensic pathology and reports no new results; it emphasizes the importance of recognizing skin manifestations in identifying types of injury.

This study found that metabolism-related genes significantly impact the prognosis and metastasis in breast cancer, and the development of prediction models may guide personalized therapeutic strategies.

This article discusses lifestyle drugs, their subjective value, and the challenges in determining who should pay for them, highlighting the need for consensus on priorities and strategies.

This review discusses the mechanisms of hair repigmentation and reports no clinical results; the authors suggest further research into topical treatments for reversing gray hair.

This review discusses segmental vitiligo as part of the vitiligo clinical spectrum and highlights its role as a model for studying repigmentation, but reports no new clinical results.

This study identified numerous drugs with potential to trigger vitiligo, cautioning that these pharmacovigilance findings need further validation and that patients on these medications should be monitored for vitiligo development.